文献速递头颈外科

头颈癌新辅助免疫治疗与化疗免疫治疗的系统综述与荟萃分析

Neoadjuvant Immunotherapy and Chemoimmunotherapy Regimens in Head and Neck Cancer: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2026-01-01

该系统综述与荟萃分析纳入23项前瞻性干预试验、751例可切除初治头颈鳞癌患者,比较新辅助化疗免疫治疗与单药或双药免疫治疗的疗效。化疗免疫治疗的MPR+CPR合并率为66%,双药免疫治疗为18%,单药免疫治疗为6%;各组1年OS率范围为88%至100%。

要点

  • 化疗免疫治疗MPR+CPR合并率66%,双药免疫治疗18%,单药免疫治疗6%。
  • 各组1年OS率范围:单药88%至96%,双药88%至96%,化疗免疫88%至100%。
  • 3至5级不良事件:单药29%,双药3.0%,化疗免疫17%。

核心结论

  • 在新辅助治疗中,化疗免疫治疗方案与单纯免疫治疗相比,在局部晚期可切除头颈鳞癌中与更高的病理和影像学缓解率相关。
  • 结果提示需要开展3期头对头试验比较这些新辅助方案。

研究设计与样本

  • 系统综述与荟萃分析,检索Medline、EMBASE、Cochrane Central Register of Controlled Trials、Cochrane Database of Systematic Reviews和Scopus,检索时间从建库至2024年10月。
  • 纳入已完成入组、以英文发表的前瞻性干预试验,仅限可切除、初治头颈鳞癌,排除未报告病理缓解或RECIST 1.1缓解的试验。
  • 共纳入23项研究、751例患者(502例[77%]男性;年龄范围27至87岁),其中化疗免疫治疗357例(47%)、双药免疫治疗102例(14%)、单药免疫治疗292例(39%)。

主要发现

  • MPR+CPR合并率:化疗免疫治疗66%(95%CI 58%-73%;I2=0.59),双药免疫治疗18%(95%CI 6%-29%;I2=0.65),单药免疫治疗6%(95%CI 3%-9%;I2<0.01)。
  • 1年OS率范围:单药免疫治疗88%至96%,双药免疫治疗88%至96%,化疗免疫治疗88%至100%。
  • 报告研究中的3至5级不良事件:单药免疫治疗61/210例(29%),双药免疫治疗2/67例(3.0%),化疗免疫治疗36/210例(17%)。

关键数值与推荐

  • 主要结局为手术时的MPR和CPR以及RECIST 1.1影像学CR,次要结局包括1年OS和毒性反应。
  • 采用二分类随机效应模型进行荟萃分析,计算免疫治疗和化疗免疫治疗组主要结局的合并比例,异质性以I2报告。

临床怎么用

  • 对于局部晚期可切除头颈鳞癌,新辅助化疗免疫治疗可能带来更高的病理和影像学缓解率,但需权衡3至5级不良事件风险。
  • 当前证据支持开展3期头对头试验,暂不足以将某一新辅助方案确立为标准治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Neoadjuvant chemoimmunotherapy has high rates of pathologic response and improved prognosis among solid tumors. Its role in head and neck squamous cell carcinoma (HNSCC) remains understudied. OBJECTIVE: To summarize the efficacy associated with neoadjuvant chemoimmunotherapy regimens in HNSCC and to compare the efficacy associated with neoadjuvant chemoimmunotherapy vs immunotherapy alone in locoregionally advanced resectable HNSCC prior to definitive surgery. DATA SOURCES: A librarian-led systematic review was conducted using multiple electronic databases, including Medline, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus, following Preferred Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA) guidelines. Databases were queried from inception to October 2024. STUDY SELECTION: Inclusion criteria included prospective interventional trials that have completed accrual, with results published in English. Only trials of resectable, treatment-naive HNSCC were included. Exclusion criteria included lack of reporting on pathologic response or Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 response. DATA EXTRACTION AND SYNTHESIS: Two investigators independently conducted title, abstract, and full-text reviews per PRISMA guidelines. Primary outcomes extracted were major pathologic response (MPR) and complete pathologic response (CPR) at surgery and complete response (CR) on imaging by RECIST 1.1. Secondary outcomes included 1-year overall survival (OS) and toxic effects. MAIN OUTCOMES AND MEASURES: A meta-analysis was performed using a binary random-effects model to determine the pooled proportion of primary outcomes in the immunotherapy and chemoimmunotherapy groups. Heterogeneity was reported as I2. RESULTS: A total of 751 patients (502 [77%] male; age range, 27-87 years) across 23 studies were included in the meta-analysis, including 357 patients (47%) who underwent chemoimmunotherapy, 102 patients (14%) who underwent dual-agent immunotherapy, and 292 patients (39%) who underwent single-agent immunotherapy. Pooled rates of MPR plus CPR were 66% (95% CI, 58%-73%; I2 = 0.59) for chemoimmunotherapy, 18% (95% CI, 6%-29%; I2 = 0.65) for dual-agent immunotherapy, and 6% (95% CI, 3%-9%; I2 < 0.01) for single-agent immunotherapy. Across all groups, 1-year OS rates ranged from 88% to 96% for single-agent immunotherapy, 88% to 96% for dual-agent immunotherapy, and 88% to 100% for chemoimmunotherapy. Grade 3 to 5 adverse events were reported in 61 of 210 patients (29%), 2 of 67 patients (3.0%), and 36 of 210 patients (17%) among the reporting studies in the single-agent immunotherapy, dual-agent immunotherapy, and chemoimmunotherapy groups, respectively. CONCLUSIONS AND RELEVANCE: These findings suggest that neoadjuvant chemoimmunotherapy regimens were associated with higher pathologic and radiographic response rates compared with immunotherapy alone in locoregionally advanced HNSCC. These results call for phase 3 trials comparing these neoadjuvant regimens head to head.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Baratz HQ, Hidalgo C, Price DL, et al. Neoadjuvant Immunotherapy and Chemoimmunotherapy Regimens in Head and Neck Cancer: A Systematic Review and Meta-Analysis. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 41817516. doi:10.1001/jamaoto.2026.0080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。